The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2020
Filed:
Nov. 11, 2016
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
Glenn Dranoff, Sudbury, MA (US);
Ryan Sullivan, Watertown, MA (US);
Matthew Vanneman, Cambridge, MA (US);
Assignee:
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7056 (2013.01); A61K 38/178 (2013.01); A61K 38/2086 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/70596 (2013.01); C07K 2319/30 (2013.01);
Abstract
Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.